Relay Therapeutics (RLAY) Other Accumulated Expenses (2021 - 2026)

Relay Therapeutics (RLAY) has 6 years of Other Accumulated Expenses data on file, last reported at $847000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 49.64% year-over-year to $847000.0 in Q1 2026; TTM through Mar 2026 was $847000.0, a 49.64% decrease from a year earlier, with the FY2025 full-year figure at $463000.0, down 76.73% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $847000.0, up from $463000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for RLAY reached as high as $26.9 million in Q3 2022 and fell as low as $463000.0 in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $8.8 million across 5 years, with a median of $1.7 million in 2024.
• Across the five-year window, Other Accumulated Expenses jumped 6504.04% in 2022 and plunged 96.96% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $26.2 million in 2022, then sank by 95.4% to $1.2 million in 2023, then surged by 65.28% to $2.0 million in 2024, then plunged by 76.73% to $463000.0 in 2025, then jumped by 82.94% to $847000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $847000.0 in Q1 2026, $463000.0 in Q4 2025, and $1.1 million in Q3 2025.